


RealRate

## PHARMACEUTICAL 2018

## Assertio Therapeutics Inc Rank 62 of 349





## PHARMACEUTICAL 2018



## Assertio Therapeutics Inc Rank 62 of 349

The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 231% points. The greatest weakness of Assertio Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 335% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	230,851
Cost of Goods Sold	0
Intangible Assets	793,873
Liabilities, Current	310,580
Liabilities, Non-Current	0
Other Assets	869
Other Compr. Net Income	14
Other Expenses	212,061
Other Liabilities	0
Other Net Income	-61,745
Property and Equipment	13,024
Research and Development	13,718
Revenues	380,724
Selling, General and Administrative Expense	195,696

Output Variable	Value in 1000 USD
Assets	1,038,617
Liabilities	310,580
Expenses	421,475
Stockholders Equity	728,037
Net Income	-102,496
Comprehensive Net Income	-102,489
Economic Capital Ratio	57%